All In Biotech

Drug Trial Radar · NCT04307576

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,430 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,430

Planned (sponsor's estimate)

Start

Jul 13, 2020

Primary completion

Jun 2033

Study completion Jun 2033

Sponsor

Lead sponsor
Mats HeymanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council; The Swedish Childhood Cancer Foundation; Pfizer; Servier; NordForsk; Aamu Pediatric Cancer Foundation; German Society for Pediatric Oncology and Hematology GPOH gGmbH; Clinical Trial Center North (CTC North GmbH & Co. KG); Belgium Health Care Knowledge Centre; Karolinska Institutet; Cancer Research UK; Fundação Rui Osório de Castro; Acreditar - Associação de Pais e Amigos das Crianças com Cancro; Grupo Português De Leucemias Pediátricas; Amgen; Nova Laboratories Limited; Danish Child Cancer Foundation; Danish Cancer Society; The Novo Nordic Foundation; Assistance Publique - Hôpitaux de Paris; Direction Générale de l'Offre de Soins; Swedish Cancer Society
First posted
Mar 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.

Conditions

  • Leukemia, Acute Lymphoblastic

Interventions

  • Omitted DoxorubicinDrug

    Omission of IV Doxorubicin

  • Omitted Vincristine+Dexamethasone pulsesDrug

    Omission of Vincristine+Dexamethasone pulses

  • Inotuzumab Ozogamicin+Standard Maintenance TherapyDrug

    Addition of IV Inotuzumab ozogamicin before Maintenance Therapy

  • ImatinibDrug

    p.o. Imatinib

  • 6-tioguanine+Standard Maintenance TherapyDrug

    Addition of p.o. 6-tioguanine to Standard Maintenance Therapy

  • BlinatumomabDrug

    IV Blinatumomab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS) for the whole protocolTime frame: 5 year estimates from the time of diagnosis will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up.
  2. Event-free survival (EFS) for the TKI interventionTime frame: From the start of TKI (day 15 or day 30), 5 year estimates will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up for all interventions except Inotuzumab-randomisation (minimum 2-year follow-up).
  3. Disease-free survival (DFS) R1 + R2Time frame: 5 and 8 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up.
  4. Disease-free survival (DFS) R3Time frame: 5 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 2-year follow-up
  5. MRD response after 1 cycle of BlinatumomabTime frame: End of first Blinatumomab infusion +/- 1 week

Locations

137 sites in 15 countries. Site status is shown where the registry gives one.

  • L'hôpital Universitaire des enfants Reine Fabiola (Huderf)

    Brussels, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc (UCL)

    Brussels, Belgium · Recruiting

  • University Hospital Antwerp

    Edegem, Belgium · Recruiting

  • University Hospital Ghent

    Ghent, Belgium · Recruiting

  • University Hospital Leuven, Dept of Paediatrics

    Leuven, Belgium · Recruiting

  • CHC MontLégia, Boulevard Patience et Beaujonc 2

    Liège, Belgium · Recruiting

  • CHR de la Citadelle

    Liège, Belgium · Recruiting

  • Aalborg University Hospital, Dept of Paediatrics

    Aalborg, Denmark · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Aarhus University Hospital, Child and Adolescent Health

    Aarhus, Denmark · Recruiting

  • Rigshospitalet, Dept of Haematology

    Copenhagen, Denmark · Recruiting

  • Rigshospitalet, Dept of Paediatrics

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital, Dept of Paediatrics

    Odense, Denmark · Recruiting

  • North Estonia Medical Centre, Dept of Haematology

    Tallinn, Estonia · Recruiting

  • Tallinn Children´s Hospital, Dept of Paediatrics

    Tallinn, Estonia · Recruiting

  • Tartu University Hospital

    Tartu, Estonia · Recruiting

  • Helsinki University Hospital, Dept of Haematology

    Helsinki, Finland · Recruiting

  • Helsinki University Hospital, Dept of Paediatrics

    Helsinki, Finland · Recruiting

  • Kuopio University Hospital, Dept of Haematology

    Kuopio, Finland · Recruiting

  • Kuopio University Hospital, Dept of Paediatrics

    Kuopio, Finland · Recruiting

  • Oulu University Hospital, Dept of Haematology, Dept of Medicine

    Oulu, Finland · Recruiting

  • Oulu University Hospital, Dept of Paediatrics

    Oulu, Finland · Recruiting

  • Tampere University Hospital, Dept of Haematology

    Tampere, Finland · Recruiting

  • Tampere University Hospital, Dept of Paediatrics

    Tampere, Finland · Recruiting

  • Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit

    Turku, Finland · Recruiting

  • Turku University Hospital, Dept of Paediatrics

    Turku, Finland · Recruiting

  • CHU Amiens Groupe Hospitalier Sud

    Amiens, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • CHRU Besançon

    Besançon, France · Recruiting

  • CHU Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, France · Recruiting

  • CHRU Brest - Morvan

    Brest, France · Recruiting

  • Centre Hospitalier Universitaire Caen

    Caen, France · Recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France · Recruiting

  • CHU Dijon Hôpital François Mitterrand

    Dijon, France · Recruiting

  • CHU de Grenoble site Nord - Hôpital Albert Michallon

    Grenoble, France · Recruiting

  • CHRU de Lille - Hôpital Jeanne de Flandre

    Lille, France · Recruiting

  • Hôpital de la mère et de l'enfant

    Limoges, France · Recruiting

  • CHU de Lyon HCL - GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP

    Lyon, France · Recruiting

  • CHU de Marseille - Hôpital de la Timone

    Marseille, France · Recruiting

  • CHU de Montpellier - Hôpital Arnaud de Villeneuve

    Montpellier, France · Recruiting

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.